  We introduce a novel audio processing architecture, the Open Voice Brain
Model (OVBM), improving detection accuracy for Alzheimer's (AD) longitudinal
discrimination from spontaneous speech. We also outline the OVBM design
methodology leading us to such architecture, which in general can incorporate
multimodal biomarkers and target simultaneously several diseases and other AI
tasks. Key in our methodology is the use of multiple biomarkers complementing
each other, and when two of them uniquely identify different subjects in a
target disease we say they are orthogonal. We illustrate the methodology by
introducing 16 biomarkers, three of which are orthogonal, demonstrating
simultaneous above state-of-the-art discrimination for apparently unrelated
diseases such as AD and COVID-19. Inspired by research conducted at the MIT
Center for Brain Minds and Machines, OVBM combines biomarker implementations of
the four modules of intelligence: The brain OS chunks and overlaps audio
samples and aggregates biomarker features from the sensory stream and cognitive
core creating a multi-modal graph neural network of symbolic compositional
models for the target task. We apply it to AD, achieving above state-of-the-art
accuracy of 93.8% on raw audio, while extracting a subject saliency map that
longitudinally tracks relative disease progression using multiple biomarkers,
16 in the reported AD task. The ultimate aim is to help medical practice by
detecting onset and treatment impact so that intervention options can be
longitudinally tested. Using the OBVM design methodology, we introduce a novel
lung and respiratory tract biomarker created using 200,000+ cough samples to
pre-train a model discriminating cough cultural origin. This cough dataset sets
a new benchmark as the largest audio health dataset with 30,000+ subjects
participating in April 2020, demonstrating for the first-time cough cultural
bias.
